Enterprise Value
2.011B
Cash
175.3M
Avg Qtr Burn
N/A
Short % of Float
12.80%
Insider Ownership
1.62%
Institutional Own.
-
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Linzess® (linaclotide) Details Irritable bowel syndrome, Inflammatory bowel disease, Bowel disorder | Approved Quarterly sales | |
Linzess® (linaclotide) Details Constipation | Approved Quarterly sales | |
Apraglutide Details Inflammatory bowel disease, Bowel disorder Big Mover™ Suspected Mover™ Susp. Mover™ | Phase 3 Data readout | |
Apraglutide (agonist of the GLP-2 receptor) Details Short bowel syndrome Big Mover™ Suspected Mover™ Susp. Mover™ | Phase 3 Data readout | |
IW-3300 Details Endometriosis, Visceral pain, Interstitial cystitis/bladder pain syndrome | Phase 2 Data readout | |
Apraglutide (agonist of the GLP-2 receptor) Details Acute graft-versus host disease | Phase 2 Data readout | |
Apraglutide Details Graft-versus-host disease | Phase 2 Data readout | |
Apraglutide (agonist of the GLP-2 receptor) Details Short bowel syndrome, Short bowel syndrome with colon-in-continuity | Phase 2 Update | |
CNP-104 Details Primary biliary cholangitis, Liver disease, Autoimmune disease | Phase 2a Data readout | |
Linaclotide Details Irritable bowel syndrome, Inflammatory bowel disease, Bowel disorder, Constipation | Failed Discontinued |